Abstract: The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposo
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
September 30, 2025
Assignee:
COMBIOXIN SA
Inventors:
Samareh Azeredo Da Silveira Lajaunias, Frédéric Lajaunias
Abstract: The present invention relates to a composition comprising a mixture of empty liposomes, wherein said mixture of empty liposomes comprises (a) a first empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight); and (b) a second empty liposome comprising sphingomyelin, for use in adjunctive treatment of 5 pneumonia in a human patient.
Type:
Grant
Filed:
April 16, 2019
Date of Patent:
August 13, 2024
Assignee:
COMBIOXIN SA
Inventors:
Samareh Azeredo Da Silveira Lajaunias, Frédéric Lajaunias